Tag: Immunotherapeutics
OSE Immunotherapeutics Presents New Data on Tedopi® in Phase 3 Clinical Trial in Patients With Advanced Non-Small Cell Lung Cancer After Failure of Immune Checkpoint Inhibitor Treatment, at ESMO Conference 2022 – 09/05/2022 at 07:30
Nantes, France – September 5, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the presentation of new analyzes on the phase 3 Atalante-1 trial of the…
OSE Immunotherapeutics announces the appointment of Alexis Vandier as Chief Executive Officer – 2022-07-13 18:00
Nantes, France – July 13, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective…
OSE Immunotherapeutics: Appoints New Chief Executive Officer
(CercleFinance.com) – OSE Immunotherapeutics announces this evening the appointment of Alexis Vandier as Chief Executive Officer, with immediate effect. He will thus succeed Alexis Peyroles who led the Company untilJanuary…
OSE Immunotherapeutics: appoints a new CEO – 07/13/2022 at 18:09
(CercleFinance.com) – OSE Immunotherapeutics announces this evening the appointment of Alexis Vandier as Chief Executive Officer, with immediate effect. He will thus succeed Alexis Peyroles who led the Company until…
OSE Immunotherapeutics will present four posters on Tedopi®, a combination of neo-epitopes in immuno-oncology, at the ASCO 2022 congress – 05/23/2022 at 18:00
Nantes, France – May 23, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale) announce…
Presentations by OSE Immunotherapeutics at upcoming international congresses in London and Boston: ‘Immuno-Oncology Summit Europe’ and ‘Tumor Myeloid-Directed Therapies Summit’ – 05/11/2022 at 6:00 p.m.
Presentations on CLEC-1, a new myeloid checkpoint inhibitor target In cancer immunotherapy Nantes, France – May 11, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been…
OSE Immunotherapeutics: new European patent – 05/02/2022 at 08:46
(AOF) – OSE Immunotherapeutics has announced that the European Patent Office (EPO) has granted a new patent that enhances the protection of CLEC-1 (among CLR – C-type lectin receptors), its…
Ose Immunotherapeutics: loss of sand but revenue up – 03/31/2022 at 08:58
(AOF) – In 2021, OSE Immunotherapeutics posted a net loss of 16.85 million euros compared to a loss of 16.555 million in 2020. The biotech’s current operating loss stood at…
Unusual volumes on the stock market today: Ose Immunotherapeutics
During this trading session on Thursday March 24, 2022, abnormal trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics share that stands out, with trading…
OSE Immunotherapeutics receives first US patent grant for OSE-279, an anti-PD1 monoclonal antibody, and its use in the treatment of cancer – 03/21/2022 at 18:00
• A grant agreement issued by the United States Patent and Trademark Office • This new patent will protect OSE-279 until 2039 Nantes, France – March 21, 2022, 6:00 p.m.…
OSE Immunotherapeutics: agreement for a patent in the USA – 03/21/2022 at 18:12
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted a first agreement to grant a patent relating to OSE-279, an anti-PD1 monoclonal antibody,…
Abnormal volumes on the Paris Stock Exchange: Ose Immunotherapeutics
During this trading session on Monday March 14, 2022, abnormal trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics share that stands out, with trading…